Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus

VENT-03 is the most advanced oral small-molecule cGAS inhibitor in clinical development Trial designed to demonstrate proof-of-concept efficacy and safety in lupus as well as the potential of VENT-03 in additional I&I diseases, cardiometabolic conditions, and inflammaging Top-line results expected in 2H 2026 WALTHAM, Mass. & MONTREAL — December 10, 2025 — (BUSINESS WIRE) — Ventus Therapeutics , a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that the first patient has been dosed in a Phase 2 trial of VENT-03 in patients with lupus. VENT-03, which was discovered using Ventus’ proprietary ReSOLVE ® platform, is the first oral small-molecule cyclic GMP-AMP synthase (cGAS) inhibitor to successfully complete a first-in-human Phase 1 study and to initiate a Phase 2 trial in patients. The cGAS pathway plays a prominent role in inflammation, cell senescence, and cell death, and has been implicated in a broad range of autoimmune and age-related inflammatory diseases as well as cardiometabolic disorders. “For the more than five million people living with lupus worldwide, the disease presents a significant burden, with painful and often debilitating symptoms that can progress to multiple organ systems — including the kidneys, heart, lungs, and brain. Treatment choices remain limited, leaving significant unmet need,” said Mona Kotecha, M.D., Chief Medical Officer of Ventus. “In addition to clinical endpoints, our Phase 2 trial incorporates a robust panel of biomarkers, including general inflammation and cardiovascular biomarkers applicable to a broad range of diseases beyond lupus. VENT-03 provides a differentiated approach to treat autoimmune disease and has the potential to become a better and more convenient once-daily oral option for patients with limited available treatments.” The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial with an open-label extension, designed to assess the efficacy and safety of VENT-03 in patients with lupus with active skin disease. The key objectives are to evaluate the safety and efficacy of VENT-03 in changing the interferon-stimulated and inflammatory gene signatures in blood and skin, in addition to evaluating the effect of VENT-03 on clinical disease severity. Additional objectives are to assess the effect of VENT-03 on systemic disease activity using accepted systemic lupus scales and the impact of VENT-03 on a robust panel of biomarkers, including those measuring cardiac health and senescence. Top-line data from the 28-day placebo-controlled portion of the trial is expected in the second half of 2026, with data from the 2-month open-label extension to follow. “This Phase 2 study of VENT-03 marks an important step in our efforts to demonstrate the broad potential of cGAS inhibition not only in lupus, but also in additional interferon-driven I&I diseases as well as cardiometabolic disorders and inflammaging,” said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “We look forward to sharing the results of this trial next year, which we believe will be a key step in unlocking the tremendous potential of VENT-03 as a pipeline-in-a-product.” About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. The presence of dsDNA in the cytoplasm is often the result of cellular dysfunction, which is a hallmark of many autoimmune and inflammatory diseases. Activation of cGAS leads to cGAMP formation, activation of STING, pronounced inflammation, and tissue damage. In both patients and preclinical models of disease, the cGAS pathway has been shown to be a key driver of lupus and other inflammatory diseases, such as rheumatoid arthritis, systemic sclerosis, dermatomyositis, and Sjögren’s disease, and is also implicated in cardiometabolic conditions and inflammaging. About Ventus Therapeutics Ventus Therapeutics is a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ® , the company has established a robust pipeline of wholly-owned programs: VENT-03, a first-in-class, oral cGAS inhibitor in Phase 2 for lupus with significant expansion opportunities in additional I&I diseases, cardiometabolic conditions, and inflammaging; VENT-02, a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson’s disease; and VENT-04, a first-in-class caspase-4/5 inhibitor in preclinical development. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn . Contacts: Media Amanda Lazaro 1AB [email protected] Investors Steve Klass 1AB [email protected] © 2026 Ventus Therapeutics. All Rights Reserved. Explore About Pipeline Platform Patients News & Events Careers Viewpoints Contact For general inquiries - [email protected] For medical inquiries - [email protected] USA 100 Beaver St, Suite 201 Waltham, Massachusetts 02453 Canada 4800, rue Lévy # 110 Saint-Laurent, H4R 2P1, QC, Canada Follow Us Legal Privacy Policy Cookie Policy click click MENU About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Viewpoints À propos Aperçu Direction Conseil d’administration Fondateurs Consultants Investisseurs Filiere de Developpement Filiere de Developpement VENT-03 VENT-02 VENT-04 Plateforme Essais cliniques Actualités et événements Dernières Nouvelles événements Dans les médias Emplois Aperçu Postes Vacants Points de vue We are using cookies to give you the best experience on our website. To find out more about the information we collect, please review our Privacy Policy . You can find out more about which cookies we are using or switch them off in settings . Nous utilisons des témoins pour vous offrir la meilleure expérience possible sur notre site Web. Pour en savoir plus sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Vous y trouverez de plus amples renseignements sur les témoins que nous utilisons, ou vous pouvez les désactiver dans les paramètres . Accept / Accepter Settings / Paramètres Close GDPR Cookie Settings Privacy Overview / Généralités sur la confidentialité Strictly Necessary Cookies / Témoins strictement nécessaires 3rd Party Cookies / Témoins tiers Powered by GDPR Cookie Compliance Privacy Overview / Généralités sur la confidentialité This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. To find out more about the information we collect, please review our Privacy Policy . Nous utilisons des témoins afin de vous offrir la meilleure expérience utilisateur possible sur notre site Web. Les informations contenues dans les fichiers témoins sont stockées dans votre navigateur. Elles servent entre autres à vous reconnaître lorsque vous revenez sur notre site Web et à nous aider à déterminer quelles sections du site vous intéressent le plus ou vous sont les plus utiles. Pour en savoir davantage sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Strictly Necessary Cookies / Témoins strictement nécessaires Strictly Necessary Cookies should be enabled at all times so that we can save your preferences for cookie settings. Les témoins strictement nécessaires doivent être activés en tout temps pour que vos préférences concernant les paramètres des témoins puissent être enregistrées. Enable or Disable Cookies Enabled Disabled 3rd Party Cookies / Témoins tiers This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Ce site Web utilise Google Analytics pour collecter des informations anonymes telles que le nombre de visiteurs sur le site et les pages les plus populaires. En maintenant ces témoins activés, vous nous aidez à améliorer notre site Web. Enable or Disable Cookies Enabled Disabled Enable All / Activer tout Reject All / Refuser tout Save Changes / Enregistrer les modifications

The release as fetched from its publisher. ventustx.com ↗